Antiseptic Treatment for Reduction of nosocomial menigitis

Not Applicable

• Conditions: Z98.2; Presence of cerebrospinal fluid drainage device

• Registration Number: DRKS00017247
• Lead Sponsor: MG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 544

Inclusion Criteria

• Indication for the installation of an external ventricular drainage or a lumbar drainage
• Age > 18 years

Exclusion Criteria

• Allergy to chlorhexidine
• not granted or withdrawn consent to the evaluation of the specific data
• prefinal status

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of infections relative to the number of patients, as compared to the total number of patients during the period of observation (incidence).

Secondary Outcome Measures

Name	Time	Method
a. the drainage-associated infection rate, given as meningoventriculitis / 1000 drainage days according to national and international standard definition (according to criteria of the CDC, KISS, modified according to Scheithauer et Bürgel),<br>b. the rate of adverse effects on application of antiseptics,<br>c. the influence of the antiseptic application on the skin microbiome of the affected region.